Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging ...View VistaGen Therapeutics, Inc VTGN investment & stock information. Get the latest VistaGen Therapeutics, Inc VTGN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Itruvone (INN Tooltip International Nonproprietary Name; developmental code name PH10), also known as pregn-4-en-20-yn-3-one, is a vomeropherine which is under development …Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those …In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therape...Feb 20, 2020 · SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced positive results from a newly published exploratory Phase 2a ... Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression ...The average VistaGen Therapeutics salary ranges from approximately $74342 per year for Office Manager to $253783 per year for Vice President.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical headquartered in California that focuses on developing novel treatments for psychiatric and Central Nervous System [CNS] disorders.VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:Maggie FitzPatrick. Maggie FitzPatrick joined our Board of Directors in July 2021 and has served as Chair since October 2023. Ms. FitzPatrick is a globally recognized corporate affairs executive who has been honored with several prestigious awards, including the Washington Business Journal’s C-Suite Executive of the Year Class (2019), PR Week ...Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals …VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...For more information: Shawn K. Singh, J.D. Chief Executive Officer VistaGen Therapeutics, Inc. www.VistaGen.com 650-244-9990 x224 [email protected] Mission Investor Relations IR Communications Atlanta, Georgia www.MissionIR.com 404-941-8975 [email protected]. Source: VistaGen Therapeutics, Inc. Released May 7, 2013PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, …VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ...The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes ...Vistagen Therapeutics, Inc. (NasdaqCM:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as ...According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI...13 Feb 2024 ... Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for ...About VistaGen VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines with for multiple CNS diseases and disorders with high unmet need. Each of VistaGen’s CNS pipeline candidates has potential as a convenient, at-home treatment with rapid-onset therapeutic benefits …The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes ...Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call. Feb 13, 2024 at 2:00 PM PST. Webcast.VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ...May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Stay up-to-date on Vistagen Therapeutics, Inc. Common Stock (VTGN) news with the latest updates, breaking headlines, news articles, and more from around the ...Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, …Presentations. Explore our Corporate presentations and learn more about how Vistagen’s visionary approach to mental health care. April 2024. Vistagen Corporate Presentation.Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ...Fasedienol is a nasal spray that reduces anxiety symptoms in social anxiety disorder (SAD) patients. The Phase 3 PALISADE-2 trial showed statistically significant …Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those …VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn't one of the 30 most popular stocks among hedge funds at the end of the third ...Vistagen announced positive results from its Phase 3 trial of fasedienol, a nasal spray for social anxiety disorder (SAD). Fasedienol showed rapid-onset reduction …The average VistaGen Therapeutics salary ranges from approximately $74342 per year for Office Manager to $253783 per year for Vice President.Fasedienol is a nasal spray that reduces anxiety symptoms in social anxiety disorder (SAD) patients. The Phase 3 PALISADE-2 trial showed statistically significant differences in SUDS score, CGI-I score, and responder rates compared to placebo.Walk-in tubs have become increasingly popular among seniors for their safety features and therapeutic benefits. However, one important consideration when purchasing a walk-in tub i...Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 ...Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol, itruvone, PH80, PH15, and ...19 Feb 2021 ... Shawn Singh has served as VistaGen's Chief Executive Officer since August 2009; he joined the Board of Directors in 2000. Mr. Singh has nearly ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of VistaGen Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, and the rules and regulations thereunder;VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...3 days ago · Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with topline results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder.Aug 21, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available ... Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call. Feb 13, 2024 at 2:00 PM PST. Webcast.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...Vistagen Therapeutics, Inc. stock has split three times since the company went public. The most recent was a 333333-for-10000000 split on 06/07/2023. View VTGN's stock split history here .Rhythmic activities are a series of movements in which individuals can take part during any steady and prominent beat. Professionals use these activities as therapeutic treatments ... Vistagen is currently preparing for Phase 2A development of AV-101, on its own or with collaborators, as a treatment for one or more neurological disorders involving the NMDAR. Multiple studies have shown AV-101 to be safe and well-tolerated, and a range of preclinical studies indicate potential in multiple indications, including levodopa ... PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate …Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those …Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI...Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), …VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year 2024 Second Quarter ...Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.2 days ago · Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ... Apr 16, 2024 · The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. About VistaGen VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated …Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety,...Sponsor: VistaGen Therapeutics, Inc. Information provided by (Responsible Party):. VistaGen Therapeutics, Inc. Study ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ...Overall, Vistagen Therapeutics Inc stock has a Growth Grade of F, Momentum Grade of B . Whether or not you should buy Vistagen Therapeutics Inc stock will ...Jul 22, 2022 · VistaGen’s CNS pipeline includes three CNS drug candidates, PH94B, PH10 and AV-101, with the potential to go beyond the current standard of care for CNS indications with high unmet need. Each of the Company’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents ...Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, … Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and co
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...6 VistaGen Therapeutics jobs. Apply to the latest jobs near you. Learn about salary, employee reviews, interviews, benefits, and work-life balance.PH15 is an investigational pherine nasal spray with a novel, rapid-onset potential mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments to improve cognitive impairment caused by mental fatigue and potentially other disorders. Vistagen believes PH15 has the potential to improve ...SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression andVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Feb 15, 2024 · VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn't one of the 30 most popular stocks among hedge funds at the end of the third ... Vistagen announced positive results from its Phase 3 trial of fasedienol, a nasal spray for social anxiety disorder (SAD). Fasedienol showed rapid-onset reduction …VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate …Vistagen Therapeutics. VTGN. $4.76. +0.06 (+1.28%) Share Price. as of April 19 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. Vistagen Therapeutics (VTGN) Stock Key Data ...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. ... Vistagen is developing an innovative pipeline of neuroscience medications with ...SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Feb. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition … These core values guide our internal processes and define our mission to radically improve mental health and well-being worldwide. Vistagen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we strive to improve the mental health care ecosystem with better outcomes ... Press Releases. Year. All Years. Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference. May 07, 2024. Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Apr 25, 2024. Vistagen to Present at the 2024 Anxiety and Depression ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, …About us. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and …`Net Income (Loss) Available to Common Stockholders, Basic` reported by Vistagen Therapeutics, Inc. to the SEC. Formalu Locations. United States. Browse By State …PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...Sep 12, 2023 · Vistagen’s pipeline includes six clinical-stage drug candidates, including its most advanced neuroactive pherine nasal spray, fasedienol (PH94B), for which Vistagen recently reported positive top-line results from its PALISADE-2 Phase 3 trial in social anxiety disorder. About PH80. PH80 is a first-in-class, neuroactive pherine nasal spray. At Vistagen, corporate responsibility is fundamental to our mission and we are committed to holding ourselves to high ethical standards. Beyond our quest to pioneer new neuroscience therapies, we strive to create a positive impact for our employees, our local communities, our patients, our stockholders, the healthcare ecosystem, and society.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful ...Significant control over Vistagen Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, …PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, … Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents ...2 days ago · Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management. Ester Salmán, MPH, joined Vistagen in May 2021 and currently serves as Vice President, Clinical Research. She brings extensive experience in steering the clinical, scientific, and strategic aspects of ongoing clinical programs, ensuring alignment with organizational goals. She joined Vistagen from Health + Hospitals, Lincoln Medical and Mental ...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.Fasedienol is a nasal spray that reduces anxiety symptoms in social anxiety disorder (SAD) patients. The Phase 3 PALISADE-2 trial showed statistically significant differences in SUDS score, CGI-I score, and responder rates compared to placebo.Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Business Wire. … Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol, itruvone, PH80, PH15, and ...Oct 2, 2023 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ... Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are …Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD). Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ... About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to …VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) ASSETS: Current assets: Cash and cash equivalents $ 51,986,400 $ 68,135,300 Prepaid expenses and other current assets 2,890,300 2,745,8003 days ago · Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 ...Press Releases. Year. All Years. Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference. May 07, 2024. Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Apr 25, 2024. Vistagen to Present at the 2024 Anxiety and Depression ...The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen ... Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment la